ArticleJCI insight2019

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Rita Tohmé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.